CN101356186A - 朊病毒-特异性拟肽试剂 - Google Patents

朊病毒-特异性拟肽试剂 Download PDF

Info

Publication number
CN101356186A
CN101356186A CNA2006800331296A CN200680033129A CN101356186A CN 101356186 A CN101356186 A CN 101356186A CN A2006800331296 A CNA2006800331296 A CN A2006800331296A CN 200680033129 A CN200680033129 A CN 200680033129A CN 101356186 A CN101356186 A CN 101356186A
Authority
CN
China
Prior art keywords
peptidomimetic
prion
complex
pathogenic
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800331296A
Other languages
English (en)
Chinese (zh)
Inventor
D·佩列兹
M·D·科诺利
R·楚克曼
M·高
R·M·希米祖
G·蒂莫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101356186A publication Critical patent/CN101356186A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800331296A 2005-09-09 2006-09-08 朊病毒-特异性拟肽试剂 Pending CN101356186A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US71576105P 2005-09-09 2005-09-09
US60/715,761 2005-09-09
US72668605P 2005-10-14 2005-10-14
US60/726,686 2005-10-14
US75893406P 2006-01-13 2006-01-13
US60/758,934 2006-01-13
PCT/US2006/035226 WO2007030804A1 (en) 2005-09-09 2006-09-08 Prion-specific peptoid reagents

Publications (1)

Publication Number Publication Date
CN101356186A true CN101356186A (zh) 2009-01-28

Family

ID=37651167

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800331296A Pending CN101356186A (zh) 2005-09-09 2006-09-08 朊病毒-特异性拟肽试剂

Country Status (14)

Country Link
US (2) US7834144B2 (cg-RX-API-DMAC7.html)
EP (2) EP1931695B1 (cg-RX-API-DMAC7.html)
JP (2) JP5209477B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080048527A (cg-RX-API-DMAC7.html)
CN (1) CN101356186A (cg-RX-API-DMAC7.html)
AU (1) AU2006287299B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0615618A2 (cg-RX-API-DMAC7.html)
CA (1) CA2621767A1 (cg-RX-API-DMAC7.html)
DK (1) DK1931695T3 (cg-RX-API-DMAC7.html)
ES (1) ES2404940T3 (cg-RX-API-DMAC7.html)
IL (1) IL189992A0 (cg-RX-API-DMAC7.html)
NZ (2) NZ566020A (cg-RX-API-DMAC7.html)
WO (1) WO2007030804A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200802186B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725639A (zh) * 2009-11-04 2012-10-10 诺华有限公司 蛋白质聚集物与单体分离中作为结合试剂的带正电物质
CN107529753A (zh) * 2015-03-11 2018-01-02 卢莫斯制药公司 环肌酸及其类似物的合成
CN110730786A (zh) * 2017-04-12 2020-01-24 先时迈纳米生物科技股份有限公司 新型类肽聚合物及使用方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2006076497A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
WO2007030804A1 (en) 2005-09-09 2007-03-15 Novartis Ag Prion-specific peptoid reagents
FR2892820B1 (fr) * 2005-11-03 2008-02-01 Diagast Soc Par Actions Simpli Procede magnetique d'immunodiagnostic pour la mise en evidence de complexe anticorps/antigene, en particulier de groupe sanguin
CA2678967C (en) * 2007-02-23 2013-10-01 The Research Foundation Of State University Of New York Rna targeting compounds and methods for making and using same
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
EP2140272A1 (en) * 2007-04-04 2010-01-06 Novartis Ag Prion elisa
JP2010523977A (ja) * 2007-04-04 2010-07-15 ノバルティス アーゲー プリオンアッセイ
JP5400050B2 (ja) * 2007-10-02 2014-01-29 シーエスエル、リミテッド 治療用抗体の精製法および使用法
US8445632B2 (en) * 2008-02-08 2013-05-21 The Regents Of The University Of California Selective poly-N-substituted glycine antibiotics
JP2011520108A (ja) * 2008-04-30 2011-07-14 ノバルティス アーゲー 病原性配座異性体についてのアッセイ
WO2010017412A1 (en) * 2008-08-06 2010-02-11 The Regents Of The University Of California Novel biomimetic peptoid polymers
WO2010098843A2 (en) 2009-02-24 2010-09-02 New York University Peptoid oligomers, pharmaceutical compositions and methods of using the same
CN102439451B (zh) 2009-06-02 2014-12-03 德克萨斯大学系统董事会 患神经退行性疾病的对象中抗体所识别的小分子的鉴定
US8952127B2 (en) 2010-06-04 2015-02-10 The Regents Of The University Of California Peptoids useful for catalyzing the mineralization of calcium carbonate
WO2013043669A1 (en) * 2011-09-21 2013-03-28 The Board Of Regents Of The University Of Texas System Peptoid compositions for the treatment of alzheimer's disease and polyglutamine expansion disorder
WO2014025785A2 (en) * 2012-08-06 2014-02-13 Trustees Of Boston University Prion protein ligands as therapeutic agents for neurodegenerative disorders
US9764953B2 (en) 2013-03-20 2017-09-19 The Regents Of The University Of California Peptoids useful for the mineralization of apatite
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
JP7026643B2 (ja) * 2016-03-09 2022-02-28 マイク-アン、エルエルシー ペプトイド親和性リガンド
EP3894380A4 (en) 2018-12-10 2022-05-04 Provivi, Inc. SYNTHESIS OF CONJUGATED DIENE PHEROMONES AND RELATED COMPOUNDS

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806627A (en) 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
US5811387A (en) 1990-05-15 1998-09-22 Chiron Corporation Peptoid mixtures
IE66205B1 (en) * 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
AU8337291A (en) 1990-08-06 1992-03-02 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
WO1993011155A1 (en) 1991-12-03 1993-06-10 Proteus Molecular Design Limited Fragments of prion proteins
WO1993023432A1 (en) 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
PL308204A1 (en) 1992-09-24 1995-07-24 Chiron Corp Synthesis of n-substituted oligomers
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
EP1416280A3 (en) 1995-09-14 2005-08-10 The Regents of the University of California Antibodies specific for native PrPsc
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
US5695005A (en) 1995-12-28 1997-12-09 Chen; Chia-Hsien Fluid dynamic crossflow cooling tower
AU713529B2 (en) 1996-04-03 1999-12-02 Stichting Dienst Landbouwkundig Onderzoek Method for the detection of prion diseases
US6586193B2 (en) 1996-04-25 2003-07-01 Genicon Sciences Corporation Analyte assay using particulate labels
EP0941122B1 (en) 1996-08-13 2003-10-29 Chiron Corporation Compositions for polynucleotide delivery
WO1998035236A2 (en) 1997-02-06 1998-08-13 Enfer Technology Limited Immunological assay for spongiform encephalopathies
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US7005295B1 (en) 1997-04-16 2006-02-28 Wyeth β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6033631A (en) 1997-04-28 2000-03-07 Chiron Corporation Synthesizer with reagent recycling
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
US6165784A (en) 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
AU3642499A (en) 1998-04-14 1999-11-01 Sugen, Inc. Ste20-related protein kinases
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
US6528269B1 (en) 1998-06-22 2003-03-04 Case Western Reserve University Immunological agents specific for prion protein (PRP)
FI982480A0 (fi) 1998-11-17 1998-11-17 Wallac Oy Immunomääritys nisäkkäiden tarttuvan spongiomuotoisen aivotaudin määrittämiseksi
JP5122705B2 (ja) 1999-01-25 2013-01-16 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
US6551843B1 (en) 1999-01-29 2003-04-22 Immunivest Corporation Methods for enhancing binding interactions between members of specific binding pairs
ES2278617T3 (es) 1999-06-23 2007-08-16 Idexx Laboratories Inc Peptidos de proteinas de prion y sus usos.
US6261790B1 (en) 1999-07-15 2001-07-17 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies
BR0012765A (pt) 1999-07-27 2002-04-02 Imp College Innovations Ltd Peptìdeo, métodos de fabricar um anticorpo, de fabricar um agente de ligação capaz de ligar-se a uma forma celular de uma proteìna de prion, de remover uma forma celular de uma proteìna de prion de uma amostra, e de usar um anticorpo e/ou agente de ligação, anticorpo, agente de ligação, uso de um anticorpo ou agente de ligação, kit, e , sequência de peptìdeo de uma forma celular de uma proteìna de prion
JP2003514773A (ja) 1999-09-28 2003-04-22 ウニヴェルジテート チューリッヒ 血清及び血漿中のプリオン結合活性を有する因子並びに伝染性海綿状脳障害を検出するための薬剤
FR2801106B1 (fr) 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
EP1267904A4 (en) * 2000-02-16 2006-02-08 Univ Northwestern POLYPEPTOIDE PULMONARY SURFACTANTS
CA2405568A1 (en) 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
IL148202A0 (en) 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
RS51523B (sr) 2000-07-07 2011-06-30 Laboratoires Serono Sa. Rana dijagnoza konformacionih bolesti
US6537548B1 (en) 2000-07-27 2003-03-25 The Regents Of The University Of California Antibodies specific for ungulate PrP
US20030092613A1 (en) 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
ES2300379T3 (es) * 2000-12-23 2008-06-16 Novartis Vaccines And Diagnostics, Inc. Procedimiento de deteccion selectiva de transfeccion de oligonucleotidos.
GB0103508D0 (en) 2001-02-13 2001-03-28 Univ Dundee Screening method and agents
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
AU2002320045B2 (en) 2001-05-31 2008-05-08 Adlyfe, Inc. Misfolded protein sensor method
EP1333708A4 (en) 2001-07-19 2008-08-13 Toray Industries CIRCUIT BOARD, CIRCUIT BOARD USAGE MEMBER AND CORRESPONDING PRODUCTION METHOD, AND SOFT FILM STRATIFICATION METHOD
EP1572894B1 (en) 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
CA2467914A1 (en) 2001-12-10 2003-06-19 Applied Research Systems Ars Holding N.V. Prion inhibiting peptides and derivatives thereof
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
CA2475247C (en) * 2002-02-07 2015-08-04 Massachusetts Institute Of Technology Anti-pathogen treatments
ES2564293T5 (es) 2002-02-28 2019-04-04 Microsens Biophage Ltd Enlazamiento de formas patológicas de proteínas priónicas
WO2003085086A2 (en) 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US20040208919A1 (en) 2002-06-13 2004-10-21 Nicolau Yves C. Vaccination against prion diseases
DE10230141B4 (de) 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
EP1382971A1 (en) 2002-07-17 2004-01-21 Pepscan Systems B.V. Detection of prion disease
EP1534746A2 (en) 2002-08-23 2005-06-01 Copenhagen Biotech Assets APS Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
AU2003265504A1 (en) 2002-10-10 2004-05-04 Heinrich Heine University Of Dusseldorf Use of monoclonal antibodies to distinguish protein conformational isoforms
ES2283608T3 (es) 2002-10-23 2007-11-01 Centre For Research And Technology Hellas/Institute Of Agrobiotechnology In.A Secuencias peptidicas de union a la proteina prionica.
AU2002352042A1 (en) 2002-11-18 2004-06-15 Prionics Ag Method for the detection of prpsc
ES2527408T3 (es) 2002-12-03 2015-01-23 North Carolina State University Ligandos de proteínas priones y procedimientos de uso
EP1457500A1 (en) 2003-03-14 2004-09-15 University of Zurich Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalophathies
JP4783727B2 (ja) 2003-04-04 2011-09-28 パソゲン リムーバル アンド ダイアグノスティック テクノロジーズ インコーポレーテッド プリオンタンパク質結合物質と使用法
WO2004092197A2 (en) 2003-04-07 2004-10-28 The Regents Of The University Of California Amyloid-specific peptides and uses thereof
JP2006524340A (ja) 2003-04-14 2006-10-26 アメリカン ナショナル レッド クロス タンパク質の構造アイソフォームに特異的なリガンドを特定するための方法
ES2398394T3 (es) 2003-08-13 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Reactivos peptídicos específicos de prión
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
JP3910569B2 (ja) 2003-08-19 2007-04-25 独立行政法人科学技術振興機構 アミロイドβ蛋白質のアミロイド線維化を増幅するための試薬
AU2004305111B2 (en) * 2003-12-19 2011-04-28 Novartis Vaccines And Diagnostics, Inc. Cell transfecting formulations of small interfering RNA, related compositions and methods of making and use
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
JP4773697B2 (ja) 2004-06-30 2011-09-14 ルネサスエレクトロニクス株式会社 Soi基板およびその製造方法ならびに半導体装置
DE102004043782A1 (de) 2004-09-08 2006-03-09 Heinrich-Heine-Universität Düsseldorf Polypeptide und Verfahren zur spezifischen Bindung von Prionen
US20060057671A1 (en) 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
AU2005209592B2 (en) 2004-09-30 2012-07-12 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
US7482172B2 (en) 2005-09-19 2009-01-27 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
WO2006076497A2 (en) 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
US20090130774A1 (en) 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
EP1853915B1 (en) 2005-02-15 2011-10-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
GB0503434D0 (en) 2005-02-18 2005-03-30 Senexis Ltd Amyloid-binding peptides, analogues and uses thereof
WO2007030804A1 (en) 2005-09-09 2007-03-15 Novartis Ag Prion-specific peptoid reagents
WO2007145589A1 (en) 2006-06-15 2007-12-21 Per Arvidsson Peptides that are capable of binding to amyloid-beta peptide.
JP5097206B2 (ja) 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド 診断および治療のためのペプチドプローブ
EP2152744A4 (en) 2007-04-26 2012-02-15 Univ Yale PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725639A (zh) * 2009-11-04 2012-10-10 诺华有限公司 蛋白质聚集物与单体分离中作为结合试剂的带正电物质
CN107529753A (zh) * 2015-03-11 2018-01-02 卢莫斯制药公司 环肌酸及其类似物的合成
CN110730786A (zh) * 2017-04-12 2020-01-24 先时迈纳米生物科技股份有限公司 新型类肽聚合物及使用方法

Also Published As

Publication number Publication date
EP2383281A2 (en) 2011-11-02
KR20080048527A (ko) 2008-06-02
EP1931695B1 (en) 2013-04-10
ZA200802186B (en) 2008-12-31
WO2007030804A1 (en) 2007-03-15
NZ594844A (en) 2013-04-26
BRPI0615618A2 (pt) 2011-05-24
ES2404940T3 (es) 2013-05-29
CA2621767A1 (en) 2007-03-15
US20120027677A1 (en) 2012-02-02
US20070087972A1 (en) 2007-04-19
EP1931695A1 (en) 2008-06-18
JP5209477B2 (ja) 2013-06-12
NZ566020A (en) 2012-08-31
US7834144B2 (en) 2010-11-16
JP2009507833A (ja) 2009-02-26
IL189992A0 (en) 2008-08-07
DK1931695T3 (da) 2013-07-01
EP2383281A3 (en) 2012-01-04
AU2006287299B2 (en) 2012-08-23
JP2012162571A (ja) 2012-08-30
AU2006287299A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
JP5209477B2 (ja) プリオンに特異的なペプトイド試薬
US20040186273A1 (en) Prion-binding ligands and methods of using same
JP4533750B2 (ja) PrPSc相互作用分子とその用途
CN102725639A (zh) 蛋白质聚集物与单体分离中作为结合试剂的带正电物质
JP2012181210A (ja) プリオン特異的ペプチド試薬を使用するelisaアッセイ
US20170349628A1 (en) Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications
US20110189692A1 (en) Assay for pathogenic conformers
JP2008527382A5 (cg-RX-API-DMAC7.html)
AU2012244255A1 (en) Prion-specific peptoid reagents
HK1163124A (en) Prion-specific peptoid reagents
MX2008003147A (en) Prion-specific peptoid reagents
AU2003272695B2 (en) PrPsc -Interacting molecules and uses thereof
EP2090664A1 (en) Neuroprotective peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis Vaccines & Diagnostic

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS VACCINES + DIAGNOSTIC TO: NOVARTIS CO., LTD.

AD01 Patent right deemed abandoned

Effective date of abandoning: 20090128

C20 Patent right or utility model deemed to be abandoned or is abandoned